Level 9, Medical School, University of Queensland Health Sciences Building, Brisbane, QLD, Australia.
Intensive Care Unit, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia.
Intensive Care Med. 2024 Nov;50(11):1873-1883. doi: 10.1007/s00134-024-07619-w. Epub 2024 Sep 23.
Dexmedetomidine increases sleep and reduces delirium in postoperative patients, but it is expensive and requires a monitored environment. Clonidine, another 2-agonist, is cheaper and is used safely for other purposes in wards. We assessed whether clonidine would improve sleep in postoperative high-dependency unit (HDU) patients.
The Clonidine at Low dosage postoperatively to Nocturnally Enhance Sleep (CLONES) study was a double-blind, placebo-controlled, parallel-group pilot effectiveness randomised trial involving adult elective surgery HDU patients in a single academic hospital. Patients received clonidine 0.3 μg/kg/h or saline placebo on the night of surgery. The primary outcome was total sleep time measured using a consumer actigraphy/photoplethysmography device.
Of the 83 randomised patients, three had no data available, leaving 80 (39 clonidine, 41 placebo) in the intention-to-treat analysis, modified for missing data. Median patient ages of the groups were similar (61 and 59 years), as were other baseline characteristics. Clonidine patients had a mean of 100.8 (95% confidence interval [CI] 38.2-163.4) minutes (p = 0.002) longer total sleep time (mean 497.2 vs. 396.4 min) and reported better sleep overall. Delirium was only observed in one patient prior to study drug infusion, and none at the end of the study. Safety outcomes were not different. Four clonidine patients had their medication ceased due to bradycardia and hypotension that required no additional treatment.
Among postoperative elective surgical patients admitted to HDU, low-dose non-titrated clonidine, compared to placebo, was associated with longer and subjectively better-quality sleep.
右美托咪定可增加术后患者的睡眠并减少谵妄,但它价格昂贵且需要在监护环境下使用。可乐定是另一种 2-激动剂,用于病房的其他用途时价格更便宜且安全。我们评估了可乐定是否会改善术后高依赖病房(HDU)患者的睡眠。
CLONES 研究(即低剂量可乐定术后夜间增强睡眠)是一项双盲、安慰剂对照、平行组的初步有效性随机试验,涉及单一学术医院的成年择期手术 HDU 患者。患者在手术当晚接受可乐定 0.3μg/kg/h 或生理盐水安慰剂治疗。主要结局是使用消费者活动/光体积描记设备测量的总睡眠时间。
83 名随机患者中,3 名患者无数据,因此 80 名(39 名可乐定,41 名安慰剂)纳入意向治疗分析,对缺失数据进行了修正。两组患者的中位年龄(61 岁和 59 岁)和其他基线特征相似。可乐定组患者的总睡眠时间平均延长 100.8 分钟(95%置信区间 [CI] 38.2-163.4)(p=0.002)(平均 497.2 分钟 vs. 396.4 分钟),并且报告的整体睡眠质量更好。在研究药物输注前仅观察到 1 例患者出现谵妄,而在研究结束时无患者出现谵妄。安全性结局无差异。4 名可乐定患者因心动过缓和低血压而停止用药,这些不良反应无需额外治疗。
与安慰剂相比,在术后接受 HDU 治疗的择期手术患者中,与非滴定的低剂量可乐定相比,患者的睡眠时间更长且主观睡眠质量更高。